Estrogen-deficiency bone loss

There are 4 papers on estrogen-deficiency bone loss in aging research: none in people yet, 3 in animals, 1 in cells.

4 papers study it5 more mention it1 finding

1 new paper in 30 daysSee all 9 papers on estrogen-deficiency bone loss

Animals3
Cells1

Interventions

1

Norcantharidin

downin N. stated1

1 study

Norcantharidin prevents estrogen-deficiency bone loss in N. stated (estrogen-deficiency model).
“our in vivo study further confirms its preventive effects on estrogen-deficiency bone loss by inhibiting osteoclast formation and functions”
Animalsestrogen-deficiency modelbone
Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling
Frontiers in pharmacologyNov 3, 2022

More on Norcantharidin

Latest

3 papers in 12 months

Biomolecules & TherapeuticsOct 29

Adenine Promotes Osteogenic Differentiation and Suppresses Osteoclastogenesis

Experiments in mouse cellsInterventions

PhytomedicineNov 8

Bisabolangelone targets CSF1R to impede osteoclastogenesis and attenuate estrogen-deficiency bone loss

Experiments in miceBones and joints

International ImmunopharmacologyDec 7

Tanshinone I attenuates estrogen-deficiency bone loss via inhibiting RANKL-induced MAPK and NF-κB signaling pathways

Experiments in miceBones and joints

Frontiers in PharmacologyNov 22

Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling

Experiments in animalsBones and joints

bioRxivJun 25

Gene III® L-Ergothioneine, alone or combined with vitamin K2, vitamin D3 and magnesium L-threonate, attenuates bone turnover, inflammatory and oxidative disturbances in ovariectomized mice

Preprint: experiments in 48 miceCholecalciferol

Biomedicine & PharmacotherapyJan 17

Functional inhibition of miR-204-5p elevated during lactation restores Runx2 and enhances osteogenesis in estrogen-deficient bone loss

Experiments in miceRUNX2

International ImmunopharmacologyNov 20

Catalpol attenuates postmenopausal osteoporosis by activating SIRT1-mediated P53 deacetylation and inhibiting CASPASE-3-driven osteoblast apoptosis

Experiments in micePostmenopausal osteoporosis

PNASNov 27

Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiency

Experiments in miceBones and joints

International ImmunopharmacologyAug 13

Dihydrotanshinone I attenuates estrogen-deficiency bone loss through RANKL-stimulated NF-κB, ERK and NFATc1 signaling pathways

Experiments in animalsBones and joints